uniQure (NASDAQ:QURE) CEO Sells $9,383,061.36 in Stock

Key Points

• uniQure CEO Matthew Kapusta sold 226,316 shares at an average price of $41.46, totaling $9.38 million, which represents a 25.78% decrease in his position.
• The company's stock recently traded at $54.31 with a market capitalization of $2.98 billion and a negative earnings per share of ($0.69).
• Analysts have favorable outlooks on uniQure, with target prices ranging from $65.00 to $80.00 following several upgrades, maintaining a consensus rating of "Buy".

uniQure N.V. (NASDAQ:QURE - Get Free Report) CEO Matthew Kapusta sold 226,316 shares of the business's stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer owned 651,454 shares of the company's stock, valued at $27,009,282.84. This trade represents a 25.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

uniQure Stock Performance

Shares of QURE traded up $1.66 during trading hours on Friday, reaching $54.31. 11,290,994 shares of the company's stock traded hands, compared to its average volume of 5,557,321. uniQure N.V. has a twelve month low of $4.45 and a twelve month high of $55.11. The business's fifty day simple moving average is $17.44 and its two-hundred day simple moving average is $14.89. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The firm has a market capitalization of $2.98 billion, a price-to-earnings ratio of -13.85 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to analyst estimates of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. Analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of uniQure in a report on Wednesday. Stifel Nicolaus boosted their price objective on uniQure from $30.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday. Wells Fargo & Company raised their target price on uniQure from $30.00 to $65.00 and gave the company an "overweight" rating in a research note on Thursday. Chardan Capital lifted their target price on uniQure from $35.00 to $76.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Cantor Fitzgerald upped their price target on shares of uniQure from $47.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $67.17.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently modified their holdings of QURE. Sanders Morris Harris LLC boosted its stake in uniQure by 12.5% in the 1st quarter. Sanders Morris Harris LLC now owns 114,887 shares of the biotechnology company's stock worth $1,139,000 after purchasing an additional 12,783 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of uniQure by 355.2% in the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock valued at $3,550,000 after purchasing an additional 261,323 shares in the last quarter. Mraz Amerine & Associates Inc. acquired a new stake in shares of uniQure in the first quarter worth $106,000. Diamond Hill Capital Management Inc. grew its holdings in shares of uniQure by 22.8% during the first quarter. Diamond Hill Capital Management Inc. now owns 82,653 shares of the biotechnology company's stock valued at $876,000 after buying an additional 15,333 shares in the last quarter. Finally, XTX Topco Ltd raised its position in uniQure by 127.3% during the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company's stock valued at $392,000 after buying an additional 20,720 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.